Company profile
ENANTA PHARMACEUTICALS INC
NASDAQ:ENTABiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EDP-305 | phase2 | — | 9 | completed, terminated |
| MODITHROMYCIN | phase2 | — | 1 | unknown |
| ZELICAPAVIR | phase2 | — | 12 | active |
| ZEVOTRELVIR | phase2 | — | 4 | no active trials |
| ALISPORIVIR | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (45)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04971512 | phase1 | terminated | 2021-08-02 | 2021-12-20 | Enanta Pharmaceuticals, Inc | A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. |
| NCT06170242 | phase2 | completed | 2023-11-20 | 2024-06-17 | Enanta Pharmaceuticals, Inc | A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model |
| NCT06847464 | phase1 | completed | 2025-01-27 | 2025-05-24 | Enanta Pharmaceuticals, Inc | A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. |
| NCT03783897 | phase1 | completed | 2018-11-27 | 2019-06-04 | Enanta Pharmaceuticals, Inc | A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects |
| NCT07482657 | phase2 | recruiting | 2026-07-09 | 2026-12-01 | Enanta Pharmaceuticals, Inc | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus |
FDA applications (0)
No records yet.